Dekhtiar Yu. M., Butenko L. L., Shevchuk H. Yu., Kurtova M. M.

STATE OF INTESTINAL BIOCENOSIS IN PATIENTS WITH ULCERATIVE COLITIS

---

Show/Download

About the author:

Dekhtiar Yu. M., Butenko L. L., Shevchuk H. Yu., Kurtova M. M.

Heading:

MICROBIOLOGY

Type of article:

Scientific article

Annotation:

Recently, the tendency to spread the incidence of ulcerative colitis continues to grow. The main etiological factors of disease development include immunological and genetic factors, intestinal biocenosis disorders, and environmental factors. This study aims to determine the features of the biocenosis of the colon in patients with ulcerative colitis. Forty patients with ulcerative colitis participated in the study: Group I – 21 patients with moderate severity and Group II – 19 with severe severity. All patients underwent a microbiological examination of the contents of the colon. In 11 out of 21 patients (52.4%) of the I group and 10 out of 19 patients (52.6%) of the II group, a decrease in Bifidobacterium spp. was established. A reduction in the concentration of Lactobacillus spp. was found in 13 out of 21 patients (61.9%) of the I group and in 16 out of 19 patients (84.2%) of the II group. Conditionally pathogenic enterobacteria of the genus Citrobacter spp. were isolated in 3 out of 31 patients (14.3%) of the I group and 3 out of 19 patients (15.8%) of the II group. In patients of the II group, Proteus spp was cultured – in 2 out of 19 patients (10.5%) and Klebsiella spp. – in 3 out of 19 patients (15.8%). A higher frequency of increased numbers of Staphylococcus aureus, Candida spp. and hemolytic Escherichia coli biovars was characteristic of patients of the II group. Patients with ulcerative colitis were characterized by dysbiotic disturbances, which worsened with increasing clinical severity of the disease. These changes were caused by a decrease in Bifidobacterium spp. and Lactobacillus spp. and an increase in the concentration of conditionally pathogenic microflora.

Tags:

Bibliography:

1. Kucharzik T, Koletzko S, Kannengiesser K, Dignass A. Ulcerative colitis-diagnostic and therapeutic algorithms. Deutsches Arzteblatt international. 2020;117(33-34):564-574. DOI: 10.3238/arztebl.2020.0564.
2. Carstens A, Dicksved J, Nelson R, Lindqvist M, Andreasson A, Bohr J, et al. The gut microbiota in collagenous colitis shares characteristics with inflammatory bowel disease-associated dysbiosis. Clin Transl Gastroenterol. 2019;10(7):e00065. DOI: 10.14309/ ctg.0000000000000065.
3. Stange EF, Schroeder BO. Microbiota and mucosal defense in IBD: an update. Expert Rev Gastroenterol Hepatol. 2019;13(10):963-976. DOI: 10.1080/17474124.2019.1671822.
4. van der Post S, Jabbar KS, Birchenough G, Arike L, Akhtar N, Sjovall H, et al. Structural weakening of the colonic mucus barrier is an early event in ulcerative colitis pathogenesis. Gut. 2019;68(12):2142-2151. DOI: 10.1136/gutjnl-2018-317571.
5. Parada Venegas D, De la Fuente MK, Landskron G, González MJ, Quera R, Dijkstra G, et al. Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. Front Immunol. 2019;10:277. DOI: 10.3389/ fimmu.2019.00277.
6. Shen ZH, Zhu CX, Quan YS, Yang ZY, Wu S, Luo WW, et al. Relationship between intestinal microbiota and ulcerative colitis: Mechanisms and clinical application of probiotics and fecal microbiota transplantation. World Journal of Gastroenterology. 2018;24(1):5-14. DOI: 10.3748/wjg.v24.i1.5.
7. Guo XY, Liu XJ, Hao JY. Gut microbiota in ulcerative colitis: insights on pathogenesis and treatment. Journal of Digestive Diseases. 2020;21(3):147-159. DOI: 10.1111/1751-2980.12849.
8. Zhu S, Han M, Liu S, Fan L, Shi H, Li P. Composition and diverse differences of intestinal microbiota in ulcerative colitis patients. Front Cell Infect Microbiol. 2022;12:953962. DOI: 10.3389/fcimb.2022.953962.
9. He XX, Li YH, Yan PG, Meng XC, Chen CY, Li KM, et al. Relationship between clinical features and intestinal microbiota in Chinese patients with ulcerative colitis. World J Gastroenterol. 2021;27(28):4722-4737. DOI: 10.3748/wjg.v27.i28.4722.
10. Zaichenko K, Gavrylyuk V, Klenina I, Sklyar T, Sokolova I, Tatarchuk O, et al. Determination of the intestinal microbiome composition in patients with crohn’s disease and ulcerative colitis of different age categories and sex. Ukrainskyi zhurnal medytsyny, biolohii ta sportu. 2020;3(25):271-281. DOI: 10.26693/jmbs05.03.273.
11. Stepanov Y, Titova M, Tatarchuk O. Large intestine microbiocoenosis disorders and the incidence of small intestinal bacterial overgrowth syndrome in patients suffering from inflammatory bowel diseases. Gastroenterologia. 2021;54(1):44-50. DOI: 10.22141/2308- 2097.54.1.2020.199141. [in Ukrainian]
12. MOZ Ukrainy. Forma pervynnoyi oblikovoyi dokumentatsiyi № 003-6/o «Informovana dobrovilʹna z·hoda patsiyenta na provedennya diahnostyky, likuvannya ta na provedennya operatsiyi ta znebolennya i na prysutnistʹ abo uchastʹ uchasnykiv osvitnʹoho protsesu». Nakaz MOZ № 549 vid 08.08.2014 zi zminamy Nakaz MOZ № 2837 vid 09.12.2020 [Internet]. Kyyiv: MOZ Ukrainy; 2020 [cited 2023 Jan 19]. Dostupno: https://zakon.rada.gov.ua/ laws/show/z0697-12#Text. [in Ukrainian]
13. Knox NC, Forbes JD, Peterson CL, Van Domselaar G, Bernstein CN. The gut microbiome in inflammatory bowel disease: lessons learned from other immune-mediated inflammatory diseases. Am J Gastroenterol. 2019;114(7):1051-1070. DOI: 10.14309/ajg.0000000000000305.
14. Pei LY, Ke YS, Zhao HH, Wang L, Jia C, Liu WZ, et al. Role of colonic microbiota in the pathogenesis of ulcerative colitis. BMC Gastroenterol. 2019;19(1):10. DOI: 10.1186/s12876-019-0930-3.

Publication of the article:

«Bulletin of problems biology and medicine», 2023 Issue 2, 169, 353-359 pages, index UDC 616.33-002.44:612.3363-07

DOI:

10.29254/2077-4214-2023-2-169-353-359